الفهرس | Only 14 pages are availabe for public view |
Abstract ERCC1 is a predictive marker for patient response to Oxaliplatin based chemotherapeutic regimen, the poor prognostic significance of KRAS is dispute, BRAF is a poor prognostic markers in colorectal cancer, KRAS & BRAF are predictive markers for therapeutic options and response to treatment in colorectal cancer In this study IHC staining was done for ERCC1, KRAS &BRAF on 3-4 um section of formalin-fixed paraffin- embedded tissues of colorectal carcinomas (adenocarcinoma, mucoid adenocarcinoma & signet cell carcinoma) for 181 colorectal (stage I-IV) patients collected from oncology & gastroenterology center ,Mansoura university in the period from January 2006 to December 2014. DFS & OS are the endpoint In this study nineteen patients (10. 5%) were stage I, fourty six patients (45. 2%) were stage II, eighty six patients (40. 5%) were stage III&thirty patients (16. 6%) were stage IV.One hundred and nine patients (60. 22%) received adjuvant therapy, sixty seven patients (37. 01%) received chemotherapy for metastatic disease. Fifty six patients had been died (30. 9%)&one hundred and twenty five had been censored (69. 1%). regarding the relation between ERCC1 and clinicopathologic tumour features ERCC1 has no relation to tumour characteristic except tumour grade in which the tumour is more low grade in ERCC1 negative cases (58. 7%) than in ERCC1 positive cases, The DFS showed no difference between ERCC1 negative and positive cases, The median PFS for patients receiving oxaliplatin-bases chemotherapy in the metastatic setting is higher in ERCC1 negative cases (median 11 months, 95% confidence interval 7-14 months) than ERCC1 positive cases & The OS showed no difference between ERCC1 negative and positive cases.There is no statistical significant relation between KRAS score and clinicopathologic features of the patients.The DFS showed no difference between KRAS negative and positive cases&the median OS is significantly prolonged in KRAS negative cases. |